SCHEMBL7362801

SCHEMBL7362801

CCOC(=O)c1c(C)cc(C)nc1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.60
SMN1; SMN2 Q16637 5/20 0.53
CYP3A4 P08684 3/20 0.53
TDP1 Q9NUW8 1/20 0.53
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 4/20 0.51
GAA P10253 4/20 0.51
HPGD P15428 3/20 0.51
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
PKM P14618 1/20 0.49
HTT P42858 1/20 0.49
NR1H2 P55055 1/20 0.49
NR1H3 Q13133 1/20 0.49
GLA P06280 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10736055 0.84 SMN1; SMN2 (0.61) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL5206808 0.84 POLB (0.58) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL26967859 0.84 NR1H2 (0.61) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL1296287 0.84 CYP3A4 (0.56) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL30367355 0.84 NR1H2 (0.61) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL9523494 0.84 ALDH1A1 (0.53) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL28860295 0.84 POLB (0.58) POLBSMN1; SMN2TDP1KDM4EALDH1A1
SCHEMBL8840383 0.83 POLB (0.57) POLBSMN1; SMN2TDP1KDM4EALDH1A1
SCHEMBL11808110 0.83 KDM4E (0.52) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL22453926 0.83 SMN1; SMN2 (0.52) POLBSMN1; SMN2CYP3A4TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191335-A1 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease ROCHE PALO ALTO LLC 2007-08-16 US disclosed
EP-0805681-A4 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1998-05-06 EP disclosed
EP-0805681-A1 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1997-11-12 EP disclosed
WO-1996022775-A1 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1996-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191335-A1 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease CCR5, CXCR1, CXCR3 POLB 2402/4885SMN1; SMN2 4099/4885CYP3A4 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.